Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 58 citing articles:

SARS-CoV-2 Vaccines, Vaccine Development Technologies, and Significant Efforts in Vaccine Development during the Pandemic: The Lessons Learned Might Help to Fight against the Next Pandemic
Chiranjib Chakraborty, Manojit Bhattacharya, Kuldeep Dhama
Vaccines (2023) Vol. 11, Iss. 3, pp. 682-682
Open Access | Times Cited: 59
Microbiota and COVID-19: Long-term and complex influencing factors
Jiaqi Gang, Haiyu Wang, Xiangsheng Xue, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 45
The effectiveness of COVID-19 vaccines in Latin America, 2021: a multicenter regional case–control study
Rebecca Kahn, Cara Bess Janusz, Márcia C. Castro, et al.
The Lancet Regional Health - Americas (2023) Vol. 20, pp. 100474-100474
Open Access | Times Cited: 22
Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study
Juan Manuel Castelli, Analía Rearte, Santiago Olszevicki, et al.
BMJ (2022), pp. e073070-e073070
Open Access | Times Cited: 29
Neutralization against Omicron subvariants after BA.5/BF.7 breakthrough infection weakened as virus evolution and aging despite repeated prototype-based vaccination 1
Hongyu Wang, Quanlin Xue, Haocheng Zhang, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 2
Open Access | Times Cited: 19
Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data
Omar Yaxmehen Bello‐Chavolla, Neftalí Eduardo Antonio-Villa, Sergio Iván Valdés‐Ferrer, et al.
International Journal of Infectious Diseases (2023) Vol. 129, pp. 188-196
Open Access | Times Cited: 17
Real-world effectiveness and factors associated with effectiveness of inactivated SARS-CoV-2 vaccines: a systematic review and meta-regression analysis
Shiyao Xu, Jincheng Li, Hongyuan Wang, et al.
BMC Medicine (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 16
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
Yaqun Fu, Jingyu Zhao, Wei Xia, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 25
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
Chao Wang, Linyi Chen, Qing‐Bin Lu, et al.
Vaccines (2022) Vol. 10, Iss. 6, pp. 920-920
Open Access | Times Cited: 24
Comparison of Biological, Pharmacological Characteristics, Indications, Contraindications, Efficacy, and Adverse Effects of Inactivated Whole-Virus COVID-19 Vaccines Sinopharm, CoronaVac, and Covaxin: An Observational Study
Sultan Ayoub Meo, Riham A. ElToukhy, Anusha Sultan Meo, et al.
Vaccines (2023) Vol. 11, Iss. 4, pp. 826-826
Open Access | Times Cited: 13
Efficacy and effectiveness of inactivated vaccines against symptomatic COVID-19, severe COVID-19, and COVID-19 clinical outcomes in the general population: a systematic review and meta-analysis
Martin Law, Sam S.H. Ho, Gigi Kwan Chi Tsang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 37, pp. 100788-100788
Open Access | Times Cited: 12
Incidence of Guillain–Barré syndrome following SARS‐CoV‐2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines
Miguel García‐Grimshaw, Javier Andrés Galnares‐Olalde, Omar Yaxmehen Bello‐Chavolla, et al.
European Journal of Neurology (2022) Vol. 29, Iss. 11, pp. 3368-3379
Open Access | Times Cited: 18
Omicron Waves in Argentina: Dynamics of SARS-CoV-2 Lineages BA.1, BA.2 and the Emerging BA.2.12.1 and BA.4/BA.5
Carolina Torres, Mercedes Nabaes Jodar, Dolores Acuña, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 312-312
Open Access | Times Cited: 11
Effectiveness of homologous or heterologous immunization regimens against SARS-CoV-2 after two doses of inactivated COVID-19 vaccine: A systematic review and meta-analysis
Xiaoyin Zhang, Jiayue Xia, Lairun Jin, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 2
Open Access | Times Cited: 11
Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study
Kim Bouillon, Bérangère Baricault, Jérémie Botton, et al.
BMJ Medicine (2022) Vol. 1, Iss. 1, pp. e000104-e000104
Open Access | Times Cited: 18
Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults
Karina A. Pasquevich, Lorena M. Coria, Ana Ceballos, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 7
Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: A systematic review and meta-analysis
Tim K. Tsang, Sheena G. Sullivan, Xiaotong Huang, et al.
American Journal of Epidemiology (2024) Vol. 193, Iss. 12, pp. 1868-1881
Open Access | Times Cited: 2
Evaluating COVID-19 vaccines in the real world
Edward J. Mills, Gilmar Reis
The Lancet (2022) Vol. 399, Iss. 10331, pp. 1205-1206
Open Access | Times Cited: 10
Vaccine effectiveness against referral to hospital after SARS-CoV-2 infection in St. Petersburg, Russia, during the Delta variant surge: a test-negative case-control study
Антон Барчук, Mikhail Cherkashin, Anna Bulina, et al.
BMC Medicine (2022) Vol. 20, Iss. 1
Open Access | Times Cited: 10
COVID-19 vaccine acceptance and hesitancy in patients with Parkinson's disease
Yifan Zhou, Zhengyu Lin, Xiaonan Wan, et al.
Frontiers in Public Health (2022) Vol. 10
Open Access | Times Cited: 10
Impact of the COVID-19 vaccination campaigns in Argentina during 2021: An observational quantification of the death probability for confirmed cases in Buenos Aires province
Guillermo Durán, Manuel Durán, Andrés Farall, et al.
Heliyon (2024) Vol. 10, Iss. 5, pp. e26310-e26310
Open Access | Times Cited: 1
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report
Karina A. Pasquevich, Lorena M. Coria, Ana Ceballos, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 4
Early vs Deferred Non–Messenger RNA COVID-19 Vaccination Among Chinese Patients With a History of Inactive Uveitis
Zhenyu Zhong, Qiuying Wu, Yuxian Lai, et al.
JAMA Network Open (2023) Vol. 6, Iss. 2, pp. e2255804-e2255804
Open Access | Times Cited: 4
Humoral and T Cell Response to SARS‐CoV‐2 Vaccination in Patients With Rheumatoid Arthritis
C. A. Isnardi, M. Landi, Leonel Cruces, et al.
Arthritis Care & Research (2023) Vol. 76, Iss. 1, pp. 120-130
Open Access | Times Cited: 4
Effectiveness of ChAdOx1 nCoV-19 and BBIBP-CorV vaccines against COVID-19-associated hospitalisation and death in the Seychelles infected adult population
Sylvie Nadine Theresa Pool, Emelyn H. Shroff, Agnes Chetty, et al.
PLoS ONE (2024) Vol. 19, Iss. 4, pp. e0299747-e0299747
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top